HomeCompareBAX vs ADBE

BAX vs ADBE: Dividend Comparison 2026

BAX yields 2.28% · ADBE yields 0.83%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADBE wins by $217.00 in total portfolio value· pulled ahead in Year 8
10 years
BAX
BAX
● Live price
2.28%
Share price
$15.80
Annual div
$0.36
5Y div CAGR
-27%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$10.26
Full BAX calculator →
ADBE
ADBE
● Live price
0.83%
Share price
$241.13
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.8K
Annual income
$87.53
Full ADBE calculator →

Portfolio growth — BAX vs ADBE

📍 ADBE pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBAXADBE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BAX + ADBE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BAX pays
ADBE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BAX
Annual income on $10K today (after 15% tax)
$193.67/yr
After 10yr DRIP, annual income (after tax)
$8.72/yr
ADBE
Annual income on $10K today (after 15% tax)
$70.50/yr
After 10yr DRIP, annual income (after tax)
$74.40/yr
At 15% tax rate, ADBE beats the other by $65.68/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BAX + ADBE for your $10,000?

BAX: 50%ADBE: 50%
100% ADBE50/50100% BAX
Portfolio after 10yr
$20.7K
Annual income
$48.90/yr
Blended yield
0.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADBE right now

BAX
Analyst Ratings
15
Buy
20
Hold
1
Sell
Consensus: Hold
Price Target
$19.75
+25.0% upside vs current
Range: $15.00 — $25.00
Altman Z
2.1
Piotroski
5/9
ADBE
Analyst Ratings
34
Buy
23
Hold
4
Sell
Consensus: Buy
Price Target
$349.65
+45.0% upside vs current
Range: $220.00 — $450.00
Altman Z
7.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BAX buys
0
ADBE buys
0
No recent congressional trades found for BAX or ADBE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBAXADBE
Forward yield2.28%0.83%
Annual dividend / share$0.36$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-27%0%
Portfolio after 10y$20.6K$20.8K
Annual income after 10y$10.26$87.53
Total dividends collected$602.00$854.00
Payment frequencyquarterlyquarterly
SectorHealthcareTechnology
Analyst consensusHoldBuy
Analyst price target$19.75$349.65

Year-by-year: BAX vs ADBE ($10,000, DRIP)

YearBAX PortfolioBAX Income/yrADBE PortfolioADBE Income/yrGap
1$10,866$166.33$10,783$82.94+$83.00BAX
2$11,750$123.31$11,621$83.59+$129.00BAX
3$12,664$90.97$12,519$84.19+$145.00BAX
4$13,617$66.89$13,480$84.76+$137.00BAX
5$14,619$49.07$14,509$85.30+$110.00BAX
6$15,679$35.94$15,610$85.80+$69.00BAX
7$16,802$26.30$16,789$86.28+$13.00BAX
8← crossover$17,998$19.23$18,051$86.72$53.00ADBE
9$19,272$14.05$19,402$87.14$130.00ADBE
10$20,631$10.26$20,848$87.53$217.00ADBE

BAX vs ADBE: Complete Analysis 2026

BAXHealthcare

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Full BAX Calculator →

ADBETechnology

Adobe Inc. operates as a diversified software company worldwide. It operates through three segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products, services, and solutions that enable individuals, teams, and enterprises to create, publish, and promote content; and Document Cloud, a unified cloud-based document services platform. Its flagship product is Creative Cloud, a subscription service that allows members to access its creative products. This segment serves content creators, workers, marketers, educators, enthusiasts, communicators, and consumers. The Digital Experience segment provides an integrated platform and set of applications and services that enable brands and businesses to create, manage, execute, measure, monetize, and optimize customer experiences from analytics to commerce. This segment serves marketers, advertisers, agencies, publishers, merchandisers, merchants, web analysts, data scientists, developers, and executives across the C-suite. The Publishing and Advertising segment offers products and services, such as e-learning solutions, technical document publishing, web conferencing, document and forms platform, web application development, and high-end printing, as well as Advertising Cloud offerings. The company offers its products and services directly to enterprise customers through its sales force and local field offices, as well as to end users through app stores and through its website at adobe.com. It also distributes products and services through a network of distributors, value-added resellers, systems integrators, software vendors and developers, retailers, and original equipment manufacturers. The company was formerly known as Adobe Systems Incorporated and changed its name to Adobe Inc. in October 2018. Adobe Inc. was founded in 1982 and is headquartered in San Jose, California.

Full ADBE Calculator →
📬

Get this BAX vs ADBE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BAX vs SCHDBAX vs JEPIBAX vs OBAX vs KOBAX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.